trending Market Intelligence /marketintelligence/en/news-insights/trending/nOjVJgeviD1jOpPoNGTu1Q2 content esgSubNav
In This List

Fortress acquires license for nervous system disorders therapy from AstraZeneca

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Fortress acquires license for nervous system disorders therapy from AstraZeneca

Fortress Biotech Inc. agreed to acquire the exclusive worldwide license of AstraZeneca PLC's experimental nervous system disorders treatment AZD7325.

Under the agreement, Cambridge, U.K.-based AstraZeneca will receive an equity stake in Fortress Biotech's newly formed partner company Baergic Bio Inc.

Additionally, New York-based Fortress Biotech will get clinical data for AZD7325 generated to date. The drug will also be renamed to BAER-101.

Moreover, Fortress Biotech entered into an agreement with Cincinnati Children's Hospital Medical Center to advance clinical development in select central nervous system disorders.